Dengue Vaccine: The Need, the Challenges, and Progress
- PMID: 26908750
- PMCID: PMC4996144
- DOI: 10.1093/infdis/jiw068
Dengue Vaccine: The Need, the Challenges, and Progress
Keywords: dengue; dengue vaccine; live virus vaccine; protective immunity; vaccine clinical trial.
Comment on
-
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.J Infect Dis. 2016 Sep 15;214(6):832-5. doi: 10.1093/infdis/jiw067. Epub 2016 Feb 16. J Infect Dis. 2016. PMID: 26908742 Free PMC article. Clinical Trial.
References
-
- Thomas SJ, Rothman AL. Trials and tribulations on the path to developing a dengue vaccine. Vaccine 2015; 33(suppl 4):D24–31. - PubMed
-
- Hadinegoro SR, Arredondo-Garcia JL, Capeding MR et al. . Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. New Engl J Med 2015; 373:1195–206. - PubMed
-
- Durbin AP, Kirkpatrick BD, Pierce KK et al. . A 12-month–interval dosing study in adults indicates that a single dose of the National Institutes of Allergy and Infectious Diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J Infect Dis 2016; 214:832–5. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
